A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

May 21, 2020

Study Completion Date

July 8, 2020

Conditions
Condylomata AcuminataPapillomavirus InfectionsSkin Diseases, ViralSkin Diseases, InfectiousSkin DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesWarts
Interventions
COMBINATION_PRODUCT

VP-102 and applicator

In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.

COMBINATION_PRODUCT

Placebo

The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin

Trial Locations (4)

46168

The Indiana Clinical Trials Center,PC, Plainfield

48346

Clarkston Skin Research, Clarkston

70816

DelRicht Research, Baton Rouge

74133

DelRicht Research, Tulsa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Instat Consulting, Inc.

OTHER

collaborator

Paidion Research, Inc.

INDUSTRY

collaborator

BioClinica, Inc.

INDUSTRY

lead

Verrica Pharmaceuticals Inc.

INDUSTRY

NCT03981822 - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | Biotech Hunter | Biotech Hunter